Our partnership with precision oncology expert Indivumed uniquely supports our mission of deciphering biological complexity and pushing the boundaries of what is possible with our proteomics solutions to accelerate drug discovery and development in oncology.

In this video, our CBO, Kristina, and Indivumed’s Senior Director Oncology Analytics, Daniel, highlight what they value and enjoy in our partnership.
 
 

This webinar reveals how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities. Jean-Marie Michot, a medical oncologist at Gustave Roussy Institute and Vito Dozio, Scientific Project Manager at Biognosys, share a study that illustrates the promise of proteomics in understanding responses to new therapies such as anti-IL-6-based treatment and the impact of comorbidities on clinical outcomes.

GenomeWebinar April 27, 2021
Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

This webinar discusses how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients. Paolo A. Ascierto, MD of Italy’s National Tumor Institute and Kamil Sklodowski of Biognosys elaborate on the promise of proteomics for addressing the unmet medical needs of melanoma patients undergoing immunotherapy.

GenomeWebinar June 16, 2021
Precision Oncology in Melanoma Patients Treated with Immunotherapy: Clinical and Technological Perspective

John L Marshall, Beth N Peshkin, Takayuki Yoshino, Jakob Vowinckel, Håvard E Danielsen, Gerry Melino, Ioannis Tsamardinos, Christian Haudenschild, David J Kerr, Carlos Sampaio, Sun Young Rha, Kevin T FitzGerald, Eric C Holland, David Gallagher, Jesus Garcia-Foncillas, Hartmut Juhl. The Oncologist.

Within the last decade, the science of molecular testing has evolved from single gene and single protein analysis to broad molecular profiling as a standard of care, quickly transitioning from research to practice. Terms such as genomics, transcriptomics, proteomics, circulating omics, and artificial intelligence are now commonplace, and this rapid evolution has left us with a significant knowledge gap within the medical community. In this paper, we attempt to bridge that gap and prepare the physician in oncology for multiomics, a group of technologies that have gone from looming on the horizon to become a clinical reality. The era of multiomics is here, and we must prepare ourselves for this exciting new age of cancer medicine.

View Publication

New: Spectronaut^® 18

Limitless Throughput. Unparalleled Efficiency

New: Spectronaut^® 18

Limitless Throughput. Unparalleled Efficiency.

Learn More